Business
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Updated Clinical Data for Patients with Metastatic Melanoma Treated in PIVOT-02 Study of Bempegaldesleukin with Nivolumab Show Durable Clinical Benefit with
About this update from Nektar Therapeutics
[{"type":"text","content":"Updated Clinical Data for Patients with Metastatic Melanoma Treated in PIVOT-02 Study of Bempegaldesleukin with Nivolumab Show Durable Clinical Benefit with Median Progression-Free Survival of 30.9 Months\n New Clinical Data Presentations for NKTR-255, a Novel IL-15 Agonist, and NKTR-262, a TLR 7/8 Agonist, Showcase Nektar's Immuno-Oncology (I-O) Pipeline\n\n\nSAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.\nNew clinical results were presented for bempegaldesleukin (BEMPEG; NKTR-214), NKTR-262 and NKTR-255. Data for BEMPEG and NKTR-262 were featured in two oral presentation sessions presented by Adi Diab, MD, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center during, respectively, the Concurrent Rapid Oral Abstract Presentation Session and the Combinatorial Therapies Session on Wednesday, November 11th. Clinical data for NKTR-255 and preclinical data for NKTR-262 were also featured in poster presentations by Dr. Nina Shah, Associate Professor, Department of Medicine, at the University of California San Francisco and Dr. Annah Rolig, Earle A. Chiles Research Institute, Providence Cancer Institute on Monday, November 9th.\nAdi Diab, MD, lead investigator of the PIVOT-02 study noted: \"These updated PIVOT-02 clinical data further validate our prior results that BEMPEG plus nivolumab provides both deep and durable responses in first-line metastatic Stage IV melanoma patients. We observed a total overall response rate of 53%, with 34% achieving a complete response, and now we have also observed a median depth of response of 78.5%, as well as a median progression free survival for the entire cohort of 30.9 months.\"\n\"The data presented at this year's SITC Meeting highlight that, by targeting key immunological processes, we have the opportunity to more effectively harness the body's immune system to fight cancer,\" said Jonathan Zalevsky, Ph.D., Head of Research and Development at Nektar Therapeutics. \"In the PIVOT-02 study of BEMPEG plus nivolumab, we observed that 90% or 18 of the 20 metastatic melanoma patients who responde...